Striatal dopamine transporter imaging correlates with depressive symptoms and Tower of London task performance in Parkinson's disease

Movement Disorders

Volumn 23, Issue 11, 2008, Pages 1580-1587

  Rektorova, Irena ^a   Srovnalova, Hana ^a   Kubikova, Radka ^a   Prasek, Jiri ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Cognitive; DaT scan; Depressive; Parkinson's disease; Tower of London task

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; ENTACAPONE; IODINE 123; LEVODOPA;

ADULT; AGE DISTRIBUTION; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC IMAGING; DISEASE DURATION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PUTAMEN; SCORING SYSTEM; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; TASK PERFORMANCE; UNITED KINGDOM;

AGED; COGNITION; CORPUS STRIATUM; DEPRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 53149084517     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22158     Document Type: Article

References (68)

1. Leenders KL, Salmon EP, Tyrrel P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
2. Brücke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000;247(Suppl 4):2-7.
3. Marshall VL, Grosset DG. The role of radiotracer imaging in Parkinson disease. Neurology 2005;65:1144-1145.
4. Piccini PP. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003;18(Suppl 7):S3-S8.
5. Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-1456.
6. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.
7. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/ carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT. Mov Disord 1999;14:436-442.
8. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
9. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
10. Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 1996;46:324-334.
11. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127:550-560.
12. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.
13. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. [Review]. Annu Rev Neurosci 1986;9:357-381.
14. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994;6: 358-370.
15. Jellinger KA. The pathology of Parkinson's disease. Adv Neurol 2001;86:55-72.
16. Owen AM, Doyon J, Dagher A, et al. Abnormal basal ganglia outflow in Parkinson's disease identified with PET: implications for higher cortical functions. Brain 1998;121:949-965.
17. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000;57:470-475.
18. Dagher A, Owen AM, Boecker H, et al. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 2001;124:1020-1032.
19. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23:6351-6356.
20. Bruck A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001;311:81-84.
21. Carbon M, Ma Y, Barnes A, et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 2004;21:1497-1507.
22. Monchi O, Petrides M, Mejia-Constain B, Strafella AP. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007;130:233-244.
23. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002;125:584-594.
24. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002;51:156-164.
25. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987;22:26-30.
26. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhemitte F, Agid Y. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg psychiatry 1989;52:201-206.
27. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 1999;115:1701-1725.
28. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999;14:711-718.
29. Taylor AE, Saint-Cyr JA, Lang AE, Kenny FT. Parkinson's disease and depression. A critical re-evaluation. Brain 1986;109: 279-292.
30. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002;17:445-454.
31. Brooks DJ, Piccini P, Imaging in Parkinson's disease: the role of monoamines in behaviour. Biol Psychiatry 2006;59:908-918.
32. Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev 2002;26:785-793.
33. Remy P, Samson Y. The role of dopamine in cognition: evidence from functional imaging studies. Curr Opin Neurol 2003;16 (Suppl. 2):S37-S41.
34. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1204-1210.
35. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005;46:227-232.
36. Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 2007;25:3132-3136.
37. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.
38. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166:141-151.
39. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
40. Folstein M, Folstein S, McHughs P. The 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-198.
41. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
42. Fahn S, Elston RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol. 2. New York: MacMillan; 1987. p 153-163.
43. Montgomery SA, Asherg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1975;134: 382-389.
44. Spreen O, Strauss E. A compendium of neuropsychological tests,: administration norms and commentary. New York: Oxford University Press; 1998.
45. Golden CJ. Stroop color and word test: a manual for clinical and experimental uses. Chicago III: Stoelting Company; 1978. p 1-32.
46. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 1982;298:199-209.
47. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun 2005;26:421-526.
48. Habradaken JB, Booij J, Sloma P, Sokole EB, van Rojen EA. Quantification and visualisation of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999;40:839-845.
49. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115:1727-1751.
50. Mayberg HS. Frontal lobe dysfunction in secondary depression. J Neuropsychiatry Clin Neurosci 1994;6:428-442.
51. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001;12:4121-4125.
52. Erixon-Lindroth N, Farde L, Wahlin TB, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res 2005;138:1-12.
53. Beauchamp MH, Dagher A, Aston JA, Doyon J. Dynamic functional changes associated with cognitive skill learning of an adapted version of the Tower of London task. Neuroimage 2003;20:1649-1660.
54. Baker SC, Rogers RD, Owen AM, et al. Neural systems engaged by planning: a PET study of the Tower of London task. Neuropsychologia 1996;34:515-526.
55. Dagher A, Owen AM, Boecker H, et al. Mapping the network for planning: a correlation PET activation study with the Tower of London task. Brain 1999;122:1973-1987.
56. Van den Heuvel OA, Groenewegen HJ, Barkhof F, et al. Frontostriatal system in planning complexity: a parametric functional magnetic resonance version of Tower of London task. Neuroimage 2003;18:367-374.
57. Morris RG, Ahmed S, Syed GM, Toone BK. Neural correlates of planning ability: frontal lobe activation during the Tower of London test. Neuropsychologia 1993;31:1367-1378.
58. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.
59. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multi-centre prospective randomized study. Eur J Neurol 2003;10:399-406.
60. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005;17:214-220.
61. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel-group randomized study. J Neurol 2006;253:555-561.
62. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115.
63. Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, García-Sánchez C. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 2007;22:62-67.
64. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1-23.
65. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992;107:394-404.
66. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
67. Ponsen MM, Stoffers B, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
68. Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson's disease. J Neurol 2000;247(Suppl 2):II103-II109.